Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 3, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
| Capital Metric | Value as of June 30, 2017 |
|---|---|
| Issued Ordinary Shares (25 pence each) | 5,371,624,009 |
| Treasury Shares | 453,205,950 |
| Total Voting Rights | 4,918,418,059 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document focuses solely on the current capital structure as of June 30, 2017.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that the total voting rights figure should be used by shareholders as the denominator for calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,918,418,059) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (453,205,950) to understand the float.
- Check the issued share capital count (5,371,624,009) against the latest annual report (Form 20-F) for consistency.